免疫抑制与代谢减重手术后艰难梭菌感染风险
基于2015—2018年MBSAQIP数据库442258例代谢减重手术患者的回顾性分析显示,使用免疫抑制剂者术后艰难梭菌感染风险显著升高(校正比值比1.956,95%CI 1.236~3.095,P<0.01),且腹腔镜Roux-en-Y胃旁路术风险高于袖状胃切除术。
要点
- 免疫抑制剂使用使减重术后艰难梭菌感染风险约翻倍。
- 腹腔镜Roux-en-Y胃旁路术感染风险高于袖状胃切除术。
- 使用免疫抑制剂者围术期应密切监测艰难梭菌感染。
核心结论
- 使用免疫抑制剂的代谢减重手术患者术后发生艰难梭菌感染的风险显著更高。
- 建议对使用免疫抑制剂的患者在术前和术后密切监测。
研究设计与样本
- 回顾性分析2015—2018年MBSAQIP数据,覆盖美国和加拿大854家附属机构。
- 初始样本760076例,排除缺失变量188106例及非Roux-en-Y胃旁路术/袖状胃成形术129712例后,最终分析442258例。
- 采用logistic回归模型按免疫抑制剂状态(阳性或阴性)计算术后艰难梭菌感染的比值比。
主要发现
- 未校正分析中,使用免疫抑制剂者术后艰难梭菌感染风险较未使用者高95%(OR 1.945;95%CI 1.230~3.075;P<0.001)。
- 校正年龄、性别、族裔、术前BMI、糖尿病状态和手术方式后,关联未受影响(校正OR 1.956;95%CI 1.236~3.095;P<0.01)。
- 完成腹腔镜Roux-en-Y胃旁路术者发生艰难梭菌感染的比值是完成腹腔镜袖状胃切除术者的2倍以上(OR 2.183;95%CI 1.842~2.587;P<0.0001)。
临床怎么用
- 对准备接受代谢减重手术并使用免疫抑制剂的患者,应评估并记录免疫抑制状态。
- 术后对使用免疫抑制剂的患者保持对艰难梭菌感染的警惕并加强监测。
- 选择Roux-en-Y胃旁路术时需考虑其较高的艰难梭菌感染风险。
局限性
- 研究为回顾性分析,可能存在未测量混杂因素。
- 分析排除了缺失变量及非目标术式的患者,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppressant use increases risk of Clostridioides (Clostridium) difficile infection. To date, no studies have analyzed the relationship between immunosuppressant use and C difficile infections after metabolic and bariatric surgery (MBS). METHODS: A retrospective analysis of the 2015-2018 MBSAQIP data was conducted. The MBSAQIP data include information from 854 affiliated practices in the US and Canada. Initial sample size was 760,076 MBS patients. After excluding participants due to missing variables (n = 188,106) and the use of surgical procedures other than Roux-en-Y gastric bypass and sleeve gastroplasty (n = 129,712), final analyses were performed on 442,258 participants. Logistic regression models generated the odds of C difficile infection developing post MBS, according to immunosuppressant status (positive or negative). RESULTS: Unadjusted logistic regression analysis showed that patients using immunosuppressants were 95% more likely to have postoperative C difficile infection (odds ratio 1.945; 95% CI, 1.230 to 3.075; p < 0.001) vs MBS patients not taking immunosuppressants. After adjusting for age, sex, ethnicity, preoperative BMI, diabetes status, and surgical procedure type, the association remained unaffected (adjusted odds ratio 1.956; 95% CI, 1.236 to 3.095; p < 0.01). Patients who completed the laparoscopic Roux-en-Y gastric bypass procedure had more than double the odds of C difficile infection developing compared with those who completed the laparoscopic sleeve gastrectomy procedure (odds ratio 2.183; 95% CI, 1.842 to 2.587; p < 0.0001). CONCLUSIONS: Our results using a population-based sample of MBS patients showed that those taking immunosuppressants have a significantly higher risk of developing Clostridioides (Clostridium) difficile infection postoperatively. These findings suggest that patients using immunosuppressants should be closely monitored both pre and post procedure.
引用
- Morales-Marroquin E, Xie L, Uppuluri M, et al. Immunosuppression and Clostridioides (Clostridium) difficile Infection Risk in Metabolic and Bariatric Surgery Patients. J Am Coll Surg. 2021. PMID: 34015452. doi:10.1016/j.jamcollsurg.2021.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。